| Company/Division name | NorthStar Medical Radioisotopes |
| Parent company | NorthStar Medical Technologies, LLC |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring implemented or to be implemented: | 2019 |
| Offshore, work was done: | Outsourced |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Netherlands |
| City reshored to: | Beloit |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Medical Equipment & Supplies |
| Product(s) reshored | Molybdenum-99 |
| What non-domestic negative factors made offshoring less attractive? | Green considerations, Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customer responsiveness improvement, Customization/Flexibility, Eco-system synergies, Government Incentives, Higher productivity, Image/brand, Lead time/Time to market, Lean/other business process improvement techniques, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training, Other |
| Government Incentive dollar amount: | $50 million * |
